CMPS vs. ARDX, ZYME, LENZ, OCS, ORIC, PRAX, COGT, CMRX, CDMO, and AVXL
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Oculis (OCS), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
In the previous week, Ardelyx had 3 more articles in the media than COMPASS Pathways. MarketBeat recorded 4 mentions for Ardelyx and 1 mentions for COMPASS Pathways. Ardelyx's average media sentiment score of 0.61 beat COMPASS Pathways' score of 0.41 indicating that Ardelyx is being referred to more favorably in the media.
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ardelyx has higher revenue and earnings than COMPASS Pathways. Ardelyx is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Ardelyx has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.
Ardelyx presently has a consensus price target of $10.89, indicating a potential upside of 159.88%. COMPASS Pathways has a consensus price target of $17.00, indicating a potential upside of 402.96%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Ardelyx.
COMPASS Pathways has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Ardelyx's return on equity of -34.45% beat COMPASS Pathways' return on equity.
Summary
Ardelyx beats COMPASS Pathways on 12 of the 16 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 7/2/2025 by MarketBeat.com Staff
Free CMPS Stock Alerts